Statistics

Total Visits

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati54

Select a period of time:

Number of views in the range

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati22

Views

Views
April 20252
May 20250
June 20250
July 202517
August 20250
September 20253
October 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States10
Brazil6
Ecuador1
Spain1
Italy1
Panama1
Portugal1
Venezuela1
 

Top cities views

Views
Almada1
Campinas1
Caçapava1
Council Bluffs1
Curitiba1
Dallas1
Edmonton1
Fazenda Rio Grande1
Guayaquil1
Hemet1